Skip to Content
Merck
CN

O2881

Oxybutynin chloride

≥98% (TLC), Muscarinic acetylcholine receptor antagonist, powder

Synonym(s):

α-Phenylcyclohexaneglycolic acid 4-(diethylamino)-2-butynyl ester hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C22H31NO3 · HCl
CAS Number:
1508-65-2
Molecular Weight:
393.95
NACRES:
NA.77
PubChem Substance ID:
57654480
UNSPSC Code:
12352200
EC Number:
216-139-7
MDL number:
MFCD00072150

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Oxybutynin chloride, ≥98% (TLC), powder

Quality Level

200

InChI key

SWIJYDAEGSIQPZ-UHFFFAOYSA-N

InChI

1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

SMILES string

Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2

assay

≥98% (TLC)

form

powder

color

white

solubility

H2O: 50 mg/mL

originator

Johnson & Johnson

Gene Information

human ... CHRM1(1128), CHRM2(1129), CHRM3(1131), CHRM4(1132), CHRM5(1133)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Muscarinic acetylcholine receptor antagonist.
Muscarinic acetylcholine receptor antagonist; inhibits proliferation of bladder smooth muscle cells, perhaps by downregulation of growth promoting genes.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000391642
0000391642
0000276178
0000276177
0000276178

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

K-S Lee et al.
International journal of clinical practice, 66(7), 663-670 (2012-06-16)
Standardised traditional outcome measures may fail to address factors that are important to patients and address irrelevant factors. Aim of this study was to assess patient-reported goals and goal achievement (GA) in the antimuscarinic treatment for overactive bladder (OAB) patients.
Adding to the evidence base: application drying time for oxybutynin chloride topical gel.
Cynthia M Sublett
Urologic nursing, 32(5), 270-271 (2013-03-12)
Lorne E Aaron et al.
Current medical research and opinion, 28(8), 1369-1379 (2012-07-10)
Evaluate patient and physician satisfaction with a novel formulation of a once-daily controlled-release (CR) oxybutynin (Uromax*) 15-mg tablet as both the initial and maintenance dose in elderly and non-elderly patients with overactive bladder (OAB). Patients not on anticholinergic treatment for
Naoki Aizawa et al.
European urology, 62(6), 1165-1173 (2012-09-18)
Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder. The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin. Female Sprague-Dawley rats
V Schuler et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 19(10), 947-951 (2012-07-25)
A broad spectrum of synthetic agents is available for the treatment of overactive bladder. Anti-cholinergic drugs show a poor compliance due to side effects. There is an increasing use of plant extracts in medicine. We have therefore investigated the inhibitory
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service